SK Biopharmaceuticals' CEO, DongHoon Lee, announced on November 29th that SK Life Science, its U.S. subsidiary, is set to conduct a symposium during the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida, from December 1st to 5th. The symposium, scheduled for December 2nd at 6 p.m., will center on "The Impact of Persistent Seizures and Strategies for Seizure Reduction or Elimination," addressing crucial treatment approaches for epilepsy patients and the existing gaps in achieving seizure remission.

Renowned speakers, including Danielle Becker, Pavel Klein, Gregory Krauss, and Patrick Kwan, are slated to present at the symposium. Their discussions will encompass innovative strategies aimed at reducing and eliminating seizures in epilepsy patients, highlighting unmet needs in achieving seizure remission.

Moreover, the symposium will feature 10 poster presentations covering diverse research areas. These presentations will include studies confirming the real-world efficacy of Cenobamate (Xcopri) as both a monotherapy and in pediatric patients with refractory epilepsy. Additionally, the research will analyze medical information, compare and evaluate the long-term efficacy (up to 60 months) of clinical participants, and provide case analyses on dose reduction of concomitant medications while using Cenobamate.

Louis Ferrari, Vice President of Medical Affairs at SK Life Science, expressed optimism, stating, "The AES symposium and poster presentations are anticipated to offer healthcare providers vital and current insights, including essential medication administration and management solutions necessary for effective patient care."